Lubiprostone plus maintenance therapy for colon cancer recurrence prevention
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests if adding an experimental drug called Lubiprostone to your usual maintenance therapy can help prevent colon or rectal cancer from coming back after surgery to remove cancer from the abdomen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or a legal decision-maker must agree to join the study and sign a consent form.
- You have a type of colon or rectal cancer that has been confirmed under a microscope as adenocarcinoma with a specific genetic pattern (pMMR or MSS).
- You have had surgery to remove cancer from your abdomen and the surgeon was able to take out most or all visible tumors.
- Your cancer has not spread to other organs outside the abdomen before starting treatment.
- You are in good general health (able to carry out daily activities without help) and your organs work well enough per the study's checks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a very low dose of radiation to a combination of immunotherapy (pucotenlimab) and chemotherapy (CAPEOX) can help shrink rectal cancer tumors that have not spread. It is for people with locally advanced rectal cancer that is pMMR (meaning the cancer cells have normal DNA repair).
This trial tests a combination of a probiotic (Lactobacillus johnsonii), two chemotherapy drugs (CapeOX), and an immunotherapy (pembrolizumab) for people with a specific type of advanced colorectal cancer that has not responded to previous treatments. It aims to see if this mix can help control the cancer.
This Phase 1/2 trial tests LYL273, a new targeted treatment, for people with metastatic colorectal (colon) cancer that has returned or not responded to standard chemo. It’s designed to see how well the drug can control the cancer and what side effects it causes.
This Phase 3 trial tests whether an added “maintenance” treatment after liver surgery can help prevent colorectal cancer from coming back. It is only for people whose blood test (ctDNA) still shows signs of cancer after their operation.
This trial tests a new form of the chemotherapy drug irinotecan (inside tiny fat particles) as a maintenance treatment for people with metastatic colorectal cancer that has responded well to initial chemotherapy. It aims to keep the cancer from growing longer.
This trial tests a new approach for people with locally advanced low rectal cancer that is pMMR type. You would receive a combination of an immunotherapy drug (anti-PD-1) with chemotherapy (FOLFOXIRI) and radiation before any surgery, to try to shrink the tumor as much as possible.
Hear when a new Peritoneal (Metastatic) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.